Marked clinical and jitter improvement after eculizumab in refractory myasthenia

Muscle Nerve. 2017 Sep;56(3):E16-E18. doi: 10.1002/mus.25620. Epub 2017 Jun 5.

Authors

Vern C Juel¹, Donald B Sanders¹, Lisa D Hobson-Webb¹, Janice M Massey¹, Jeffrey T Guptill¹, Fanny O'Brien^{2

3}, Jing Jing Wang^{2

3}, James F Howard Jr⁴

Affiliations

¹ Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA.
² Department of Clinical Research, Alexion Pharmaceuticals, Cheshire, Connecticut, USA.
³ Department Global Medical Affairs, Alexion Pharmaceuticals, Cheshire, Connecticut, USA.
⁴ Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Electromyography / drug effects*
Electromyography / trends
Humans
Male
Middle Aged
Myasthenia Gravis / diagnosis*
Myasthenia Gravis / drug therapy*
Myasthenia Gravis / physiopathology
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
eculizumab

Grants and funding

K23 NS085049/NS/NINDS NIH HHS/United States